Effect of mild and moderate hepatic impairment (defined by Child–Pugh classification and National Cancer Institute Organ Dysfunction Working Group criteria) on …
H Zahir, J Greenberg, C Hsu… - The Journal of …, 2022 - Wiley Online Library
Pexidartinib is a novel oral small‐molecule tyrosine kinase inhibitor targeting the colony‐
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
H Zahir, J Greenberg, C Hsu… - Clinical …, 2023 - Wiley Online Library
Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - Springer
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team
C McCabe, H Wright, K Polson, AJ Wagner - Orphanet Journal of Rare …, 2023 - Springer
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor or other solid tumors
O Yin, AJ Wagner, J Kang, W Knebel… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is a kinase inhibitor that induces tumor response and improvements in
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: implementation of model‐informed drug …
H Zahir, O Yin, C Hsu, AJ Wagner… - Clinical …, 2023 - Wiley Online Library
Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
TURALIO® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment
C Dharmani, O Fofah, M Fallon, AW Rajper… - Future …, 2024 - Taylor & Francis
Aim: Hepatic safety data assessment from the TURALIO®(pexidartinib) Risk Evaluation and
Mitigation Strategy (tREMS) Program. Methods: Retrospective 3-year assessment (August …
Mitigation Strategy (tREMS) Program. Methods: Retrospective 3-year assessment (August …
Evaluation of potential drug‐drug interaction risk of pexidartinib with substrates of cytochrome P450 and P‐glycoprotein
H Zahir, F Kobayashi, C Zamora… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
S Nakayama, V Lukacova, S Tanabe… - Clinical …, 2024 - Wiley Online Library
Pexidartinib is a systemic treatment for patients with tenosynovial giant cell tumor not
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …
Eco-Friendly, Simple, Fast, and Sensitive UPLC-MS/MS Method for Determination of Pexidartinib in Plasma and Its Application to Metabolic Stability
E Ezzeldin, M Iqbal, YA Asiri, GAE Mostafa, AYA Sayed - Molecules, 2022 - mdpi.com
Pexidartinib is the first drug approved by the US Food and Drug Administration specifically to
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …